U.S. Markets closed

Genmab A/S (GNMSF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
224.500.00 (0.00%)
At close: 12:38PM EDT
  • Did anyone else see $GNMSF report from http://wefunder.com/bchi/?s=GNMSF ? It had some interesting information. "rht" Trading stocks investing.

    Invest in Buying Collective Holdings Inc. | Organic, non-GMO foods at wholesale prices, delivered to your doorstep on @wefunder
    We're focused on (1) building the Buying Collective of CLEAN food shoppers through the Health Merchant® network; (2) sourcing CLEAN foods at the lowest possible cost; and (3) selling CLEAN foods with direct, free delivery to households that are part
  • http://yugestocks.com/?s=GNMSF has an alert for $GNMSF. Did anyone happen to see it as well? Looking for some good positive information from the company! Making money trading stocks. Helga's rule: say no

    Yuge Stocks: Trading Stocks and Making Money
    Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
  • Darzalex expected to reach 9 billion market.
  • https://endpts.com/genmab-outlines-a-megablockbuster-future-for-itself-and-jj-as-darzalex-gains-market-traction/

    Genmab outlines a megablockbuster future for itself and J&J as Darzalex gains market traction
    J&J tends to be a cautious player when it comes to projecting peak sales for a top drug prospect. But its partners at Genmab clearly believe that the sky’s the limit on their myeloma drug Darzalex (daratumumab). Initially pushed back to the last line
  • Darzalex has shown spectacular results with relapsed multiple myeloma but that is just the tip of the iceberg. Approval will soon be expanded to include earlier stages which is a much larger market. The market can also be expanded to include non-small cell lung, head and neck, pancreatic, colorectal and triple negative breast cancers. A new partnership with Bristol Meyers will test it with Opdivo for those indications. The sky is the limit!


    Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
    HORSHAM, Pa., Jan. 5, 2017 /PRNewswire/ -- Janssen Biotech, Inc. today announced that the company has entered a...
  • The FDA is doing a priority review of expanding its approval of Darzalex to greatly expand the market to include earlier stages. The decision is expected in February.


    UPDATED: J&J's Darzalex posts 'standout' data in myeloma, nabs FDA priority review | FiercePharma
    Johnson & Johnson may have a hotter med in Darzalex than previously thought. Already approved for multiple myeloma patients who’ve failed on three previous regimens, Darzalex is waiting on an FDA nod for broader use--and with new data released Thursd
  • Info for $GNMSF on http://otc.ninja/?s=GNMSF

  • Excellent company. Worth at least 10b U$.